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Abstract: Glutaredoxin-2 (Grx2) modulates the activity of several 
mitochondrial proteins in cardiac tissue by catalyzing deglutathio-
nylation reactions. However, it remains uncertain whether Grx2 is 
required to control mitochondrial ATP output in heart. Here, we 
report that Grx2 plays a vital role modulating mitochondrial ener-
getics and heart physiology by mediating the deglutathionylation 
of mitochondrial proteins. Deletion of Grx2 (Grx2−/−) decreased 
ATP production by complex I-linked substrates to half that in 
wild type (WT) mitochondria. Decreased respiration was associ-
ated with increased complex I glutathionylation diminishing its 
activity. Tissue glucose uptake was concomitantly increased. Mi-
tochondrial ATP output and complex I activity could be recovered 
by restoring the redox environment to that favoring the degluta-
thionylated states of proteins. Grx2−/− hearts also developed left 
ventricular hypertrophy and fibrosis, and mice became hyperten-
sive. Mitochondrial energetics from Grx2 heterozygotes (Grx2+/−) 
were also dysfunctional, and hearts were hypertrophic. Intrigu-
ingly, Grx2+/− mice were far less hypertensive than Grx2−/− mice. 
Thus, Grx2 plays a vital role in modulating mitochondrial metab-
olism in cardiac muscle, and Grx2 deficiency leads to pathology. 
As mitochondrial ATP production was restored by the addition of 
reductants, these findings may be relevant to novel redox-related 
therapies in cardiac disease. 
Keywords: Bioenergetics, Cardiac Hypertrophy, Cardiac Metab-
olism, Glutathionylation, Mitochondria, Redox, Glutaredoxin-2, 
Glutathione, Oxidative Phosphorylation
Abbreviations: ROS — reactive oxygen species, Grx — glutare-
doxin, OXPHOS — oxidative phosphorylation, RCR — respi-
ratory control ratio, PSSG — protein glutathione disulfide, Mn-
SOD — manganese superoxide dismutase, FCCP — carbonyl 
cyanide p-trifluoromethoxyphenylhydrazone, ANOVA — analy-
sis of variance, PET — positron emission tomography, β-MetOH 
— β-mercaptoethanol
Introduction
Glutathionylation reactions have emerged as key post-
translational modifications required to control protein func-
tion in response to changes in redox (1). These modifications 
involve the formation of a disulfide bridge between glu-
tathione (GSH) and an available protein cysteine thiol. Re-
actions can either proceed nonenzymatically or enzymat-
ically, depending on cell conditions (2). For instance, the 
former occurs mostly during oxidative stress when 2GSH/
GSSG is ~1, and levels of reactive oxygen species (ROS)2 are 
high. Nonenzymatic glutathionylation reactions are non-
specific and can lead to the hyper-glutathionylation of pro-
teins, altering their activity (3–5). Enzymatic glutathionyl-
ation reactions, however, are tightly controlled and highly 
specific post-translational modifications that occur normally 
in response to fluctuations in local redox environments (6–
8). The glutaredoxin (Grx) proteins are currently thought to 
be the chief enzymes that catalyze these reactions (9). Spe-
cifically the Grx proteins catalyze the deglutathionylation of 
protein glutathione disulfide (PSSG) mixtures. In the cyto-
sol, Grx1 is required to catalyze the deglutathionylation of 
target proteins (10). Grx1 catalyzes the deglutathionylation 
of protein targets in two steps as follows: 1) N-terminal cys-
teine on Grx1 deglutathionylates PSSG via a thiol disulfide 
exchange reaction yielding the deglutathionylated protein 
(PSH) and a Grx1-glutathionylated protein (SSG) interme-
diate; 2) Grx1-SSG binds GSH, and the glutathionyl moiety 
is removed regenerating Grx1 and producing GSSG (11). Al-
though the mechanistic details of the catalytic reaction still 
require clarification (12), several models for the characteris-
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Background:  Mitochondrial proteins are controlled by glutaredoxin-2 (Grx2)-mediated deglutathionylation reactions. 
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tic nucleophilic displacement ping-pong mechanism of Grx1 
have been proposed and include a glutathione scaffold, glu-
tathione activator, and an oxidative half-reaction (12). How-
ever, emerging evidence has also suggested that the Grx en-
zymes can also catalyze protein glutathionylation (13). This 
can be mediated via the stabilization of a glutathione thiyl 
radical that is then subsequently transferred to an available 
protein thiol (13). 
Mitochondrial processes are particularly susceptible to 
regulation by glutathionylation. This is due to the unique 
physical properties of the matrix environment. The slight 
alkalinity of the matrix ionizes protein thiols increasing re-
activity toward glutathione (14). Mitochondria also contain 
high amounts of protein thiols (60–90 mm), reduced gluta-
thione (GSH; ~5 mm), and are a major source of ROS, fac-
tors that render protein glutathionylation reactions more 
favorable (14, 15). Mitochondrial redox environment fluc-
tuations also occur during fuel oxidation, electron transfer, 
and the formation of ROS. The thiol oxidoreductase glutare-
doxin-2 (Grx2), which has ~34% homology to Grx1, was re-
cently identified as the enzyme required to catalyze degluta-
thionylation reactions in mitochondria (16–19). The catalytic 
cycle of Grx2 is also quite similar to Grx1 except that the 
Grx2-SSG intermediate can be reduced by NADPH and thio-
redoxin reductase (20). It is also important to point out that 
unlike Grx1, Grx2 complexes iron (Fe), which is required to 
modulate its activity (21) (Grx2 regulation by coordination 
of 2Fe-2S cluster was recently reviewed in detail in Refs. 22, 
23). Intriguingly, Grx2 has been shown to catalyze both the 
deglutathionylation and glutathionylation of target proteins 
in mitochondria. The reversible nature of Grx2 is associated 
with its sensitivity to changes in 2GSH/GSSG as follows: a 
high 2GSH/GSSG promotes protein deglutathionylation and 
a low 2GSH/GSSG activates Grx2 glutathionylase activity 
(24, 25). The main target for Grx2 in mitochondria is complex 
I (24). Increases and decreases in 2GSH/GSSG prompt Grx2-
mediated deglutathionylation and glutathionylation of com-
plex I, which then alters its activity and superoxide produc-
tion (24). Complex I has also been shown to be a Grx2 target 
in lens epithelia and liver mitochondria (26–28). UCP3 has 
also been shown to be targeted by Grx2 in skeletal muscle 
(28). 2-Oxoglutarate dehydrogenase may also be targeted by 
Grx2 because it can be deglutathionylated in vitro by exoge-
nously added Grx1 (29). 
The heart muscle turns over ~30 kg of ATP daily (30). 
Clearly, mitochondrial ATP production is central to heart 
function. A variety of control mechanisms converge on mi-
tochondria to adjust ATP output. Changes in redox due to 
temporal differences in mitochondrial metabolism (ROS pro-
duction, NAD(P)H levels, and GSH and GSSG levels) can 
feedback to modulate oxidative phosphorylation. A decrease 
in 2GSH/GSSG could prompt glutathionylation of cardiac 
mitochondrial proteins, although a reductive glutathione ra-
tio has the opposite effect (24, 31). A number of glutathionyl-
ation targets in cardiac mitochondria have been identified, 
including complex I subunit NDUSF1, complex II subunit 
succinate dehydrogenase B, 2-oxoglutarate dehydrogenase, 
and ATP synthase α subunit (25, 29, 32, 33). These proteins 
fulfill important energetic roles in cardiac mitochondria, in-
cluding energy substrate metabolism and oxidative phos-
phorylation. Alterations in the control of mitochondrial glu-
tathionylation can have profound physiological effects. Grx2 
overexpression prevents doxorubicin-induced cardiac in-
jury, and this is associated with recovery of mitochondrial 
respiration (34). Irregularities in the glutathionylation of the 
ATP synthase α subunit are associated with cardiac dysfunc-
tion (33). In addition, glutathionylation of complex I compro-
mises aerobic metabolism in the heart, contributing to the 
development of cardiac dysfunction (31). Ischemic reperfu-
sion injury also alters the glutathionylation state of complex 
II (32). Thus, the disruption of controlled protein glutathio-
nylation reactions can compromise ATP output by cardiac 
mitochondria, potentially leading to disease. 
Despite the number of glutathionylation targets in cardiac 
mitochondria, it still remains unknown if reversible glutathi-
onylation can regulate oxidative phosphorylation (OXPHOS; 
ATP output). It is also unclear if deregulation of protein de-
glutathionylation reactions (e.g. loss of Grx2 deglutathionylase 
activity) in mitochondria can contribute to the development 
of cardiac dysfunction. In this study, we examine the impor-
tance of Grx2 function in cardiac physiology and metabolism. 
We used germ line Grx2 whole body knock-out (Grx2−/−, 
Grx2-deficient) mice, which we have recently characterized 
(28). In our previous study, we found that Grx2 deficiency did 
not induce any major defects (linear growth, food intake, and 
liver physiology), but we did note that hearts weighed sig-
nificantly more (28). In this study, we examined the impact 
of Grx2 deficiency on cardiac metabolism and function. We 
found that OXPHOS was substantially decreased in cardiac 
mitochondria from Grx2-deficient mice. The decrease in OX-
PHOS was due to the glutathionylation of complex I resulting 
in decreased activity. These biochemical effects were reversed 
with dithiothreitol (DTT), a reductant known to prompt pro-
tein deglutathionylation (35, 36), thereby favoring deglutathi-
onylation. The biochemical changes in OXPHOS were asso-
ciated with development of cardiac abnormalities, including 
left ventricular hypertrophy, fibrosis, and a metabolic shift to-
ward increased glucose uptake. We conclude that Grx2-medi-
ated reversible glutathionylation is critical in modulating mi-
tochondrial ATP output in cardiac muscle, and disruption of 
this process is pathological. 
Experimental Procedures
Animals. Studies were conducted on male C57BL/6 wild 
type (WT) and Grx2 whole body knock-out (Grx2−/−) mice 
aged 9–12 weeks that were backcrossed for over 10 genera-
tions into the C57BL/6 strain. Mice were fed ad libitum a stan-
dard diet (44.2% carbohydrate, 6.2% fat, 18.6% crude protein; 
diet T.2018, Harlan, Indianapolis, IN). All experiments were 
performed according to the principles and guidelines of the 
Canadian Council of Animal Care, and the study was ap-
proved by the Animal Care Committee of the University of 
Ottawa. Mice were genotyped for Grx2 prior to experimenta-
tion. Body and heart weights along with femur lengths were 
measured. Serum hemoglobin levels were measured using a 
kit purchased from Sigma, and assays were conducted as de-
scribed by the manufacturer. For time profile experiments, 
mice were aged either 6 or 10 weeks. 
Echocardiography. For M-mode and pulsed-wave Dop-
pler echocardiography, mice were anesthetized (2.0% isoflu-
rane, 80 ml/min 100% O2); anterior chests were shaved, and 
two-dimensional guided M-mode and pulsed-wave Doppler 
echocardiography were performed using a VEVO 2100 sys-
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tem (Visual Sonics, Amsterdam) with a 30-MHz linear ar-
ray transducer. Images and videos were analyzed using the 
VEVO 2100 analysis software. 
MicroPET Imaging. Small animal PET FDG imaging 
was conducted with the InveonTM DPET small animal scan-
ner (Siemens, Knoxville, TN). Mice were scanned under an-
esthesia (2–2.5% isoflurane, 2–2.5 ml/min oxygen) in a fed 
state. A 60-min list-mode acquisition was started together 
with a 10–20-s tail vein injection of FDG (25.9 ± 6.94 MBq in 
150 μl). List data were sorted into 26 dynamic frames (12 × 
10, 3 × 60, and 11 × 300s) and reconstructed using OSEM3D 
with 10 iterations, 16 subsets, zoom of 2.5 with a 128 × 128 
matrix, resulting in a 0.35-mm transaxial pixel size. Images 
were corrected for radioactive decay, random coincidences, 
and dead-time losses using the vendor software (IAW ver-
sion 1.5). Blood glucose was measured prior to FDG injection 
with Advantage blood glucose strips (AccuChek, Roche Di-
agnostics). Myocardial time activity curves were compared 
using standard uptake values calculated by dividing the ac-
tivity concentration in the region of interest (Bq/ml) by the 
activity concentration per body weight injected into the an-
imal (Bq/g) (Siemens IRW software). Patlak kinetic analysis 
of reconstructed images was performed on the myocardium 
at 10–40 min as described previously with FlowQuant semi-
automated software (63). Regional rate of myocardial glu-
cose uptake (rMGU) was determined for each animal using 
the Equation 1,
rMGU = Ki × BG/LC(mmol/min/g)                (1)
where Ki is the Patlak uptake rate constant; BG is the blood 
glucose concentration, and LC is the lumped constant equal 
to 0.67, which accounts for differences in the uptake and 
phosphorylation of FDG versus glucose. 
Fibrosis Determinations. Hearts were placed in 10% 
formalin for 48 h and then in 70% ethanol prior to paraf-
fin embedding. Transverse sections were taken at the ver-
tical midpoint of the heart (4 μm each), and deparaffinized 
sections were stained with Sirius Red, which stains fibril-
lar types 1 and 3 collagen. Analysis of the extent of fibro-
sis was determined using Zen software (Carl Zeiss Micros-
copy) whereby thresholds were set for collagen-stained 
areas, and identified areas were expressed as a percentage 
of the total tissue area. 
Blood Pressure. Systolic blood pressure was determined 
using a BP-2000 Blood Pressure Analysis SystemTM (Visitech 
Systems; Apex, NC). This is a noninvasive computerized tail-
cuff system. Mice (age of 10 weeks) were placed on the BP-
200 platform (pre-warmed to 30 °C), and tails were passed 
through the tail cuffs. Mice were acclimated to the system 
daily for 5 days. After acclimation, blood pressure measure-
ments were conducted between 9:00 and 11:00 a.m. daily for 
5 days. Each day, mice were further acclimatized for 10 min 
prior to the 20-min measurement period. 
Mitochondrial Ultrastructure. Electron microscopic im-
aging was performed on fixed and stained sections of the 
left ventricle. For heart fixation, mice were fully anesthetized 
using isofluorane (~5%, O2 at ~1 liter/min). The left ventri-
cle near the apex was punctured with a 25-gauge needle, 
and a small incision was made in right atrium for fluid ef-
flux. Hearts were then perfused slowly with heparinized sa-
line until the efflux was clear and then perfused with fixative 
(2.5% glutaraldehyde + 2% formaldehyde in PBS). Hearts 
were excised, placed in fixative, and stored at 4 °C. A Leica 
Ultracut E ultramicrotome was used to section the tissue, 
and sections were counterstained with lead citrate and ura-
nyl acetate. Images were collected using JEOL 1230 transmis-
sion electron microscopy at 60 kV. 
Mitochondrial Isolation. Mitochondria were isolated 
as described previously (37). All steps were performed 
on ice or at 4 °C. Hearts were excised and placed immedi-
ately in homogenizing buffer (HM: 220 mm mannitol, 70 
mm sucrose, 5 mm HEPES, 1 mm EGTA, 10 mm pyruvate, 
2 mm malate or 0.5 mm l-carnitine, 2 mm malate, pH 7.2). 
On the day of experiments, HM was supplemented with 
1% (w/v) defatted BSA + 2 units of subtilisin A. Tissue 
was cut into small pieces and washed four times in HM. 
Pieces were minced and then homogenized using the Pot-
ter-Elvehjem method. Homogenates were placed in cen-
trifugation tubes and spun at 18,000 × g for 9 min. Pellets 
were resuspended in fresh HM and centrifuged at 800 × 
g for 9 min. Supernatants were carefully transferred into 
new centrifugation tubes and spun at 10,000 × g for 9 min. 
The mitochondrial pellets were resuspended in a 100 μl of 
HM devoid of BSA and subtilisin A. Protein content was 
determined by a Bradford assay. Mitochondria were then 
diluted according to protein equivalents (micrograms of 
mitochondrial protein/ml) for various assays. 
Mitochondrial Bioenergetics. The bioenergetics of iso-
lated mitochondria were studied in a Seahorse XF24 extra-
cellular flux analyzer (Seahorse Biosciences; North Billerica, 
MA) using a method adapted from Refs. 28, 37. Mitochon-
dria were diluted to 200 μg/ml in BSA-free HM, and 50 μl 
(~10 μg of mitochondria) was loaded into each Seahorse TC 
plate well. Mitochondria were attached to the plate surface 
by centrifugation at 2000 × g for 20 min at 4 °C, incubated for 
10 min in reaction buffer (HM containing 10 mm KH2PO4, 
5 mm MgCl2, 0.2% w/v defatted BSA, with/without 10 mm 
DTT + 10 mm pyruvate, 2 mm malate or 0.1 mm palmitoyl-
carnitine, 0.1 mm palmitate-BSA complex, 2 mm malate), 
and loaded into the XF24 Analyzer. 
Bioenergetic parameters were measured as described 
previously (28). Following measurement of state 2 respi-
ration (presence of substrate only), mitochondria were se-
quentially treated with ADP (0.1 mm), oligomycin (2.5 μg/
ml), FCCP (8 μm), and antimycin A (4 μm) to test state 3 
(phosphorylating respiration), state 4O (proton leak-depen-
dent respiration), maximal respiration (uncoupled), and 
respiration independent of the respiratory chain, respec-
tively. Respiratory control ratio (RCR) values were calcu-
lated by dividing the absolute rate of state 3 respiration by 
state 4O respiration. ADP titration and cytochrome c titra-
tion experiments were performed as described previously 
(28) to determine whether mitochondrial outer membranes 
were intact. All values were corrected for background O2 
consumption and any O2 consumption not associated with 
the respiratory chain (antimycin A). 
2GSH/GSSG. The potential of the 2GSH/GSSG pair 
was determined as described previously (38). Isolated mi-
tochondria were diluted to 0.5 mg/ml in ice-cold 0.5% 
(v/v) perchloric acid solution and incubated on ice for 10 
min. Samples were then centrifuged at 10,000 × g for 10 
min at 4 °C to remove any precipitate. The supernatant 
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was injected into an Agilent HPLC system equipped with 
a Pursuit C18 column (150 × 4.6 mm, 5 μm; Agilent Tech-
nologies) operating at a flow rate of 1 ml/min. The mo-
bile phase consisted of 1% trifluoroacetic acid diluted in 
double distilled H2O and mixed with HPLC-grade meth-
anol in a 90:10 ratio. Retention times for GSH and GSSG 
were estimated by injecting standard solutions. Abso-
lute amounts of GSH and GSSG were determined by in-
tegrating the area under each peak using Agilent Chem-
Station software. Values were interpolated from standard 
curves to give nanomoles of GSH and GSSG. Values were 
used to calculate millimolar amounts by assuming a mito-
chondrial volume of 0.75 μl (28, 39). Resulting values were 
used to calculate 2GSH/GSSG and the Eh of the pair as 
shown in Equation 2, 
       GSSG + 2e– + 2H– → 2GSH
Eh = –240 –
 61.5 mV  log [GSH]
2                 (2)                                                         2               [GSSG]  
at 37 °C. 
Glutathionylated Proteome. Protein glutathionyl-
ation levels were determined as described previously 
(28, 38). Freshly isolated mitochondria were treated with 
25 mm N-ethylmaleimide to block unoccupied glutathio-
nylation sites, and the suspension was diluted to 2 mg/
ml in Laemmli buffer. Samples were electrophoresed on 
12% SDS gels under nonreducing conditions. Upon com-
pletion, proteins were electroblotted to nitrocellulose 
membranes, blocked for nonspecific binding sites, and 
probed with PSSG antiserum (1:500, Virogen). Note that 
the antibody was diluted in 5% (w/v) nonfat skim milk 
dissolved in TBS-T (Tris-buffered saline + 0.1% (v/v) 
Tween 20) and incubated under constant agitation over-
night at 4 °C. Membranes were then probed with anti-
mouse HRP-conjugated secondary antibody diluted in 5% 
(w/v) nonfat skim milk in TBS-T for 1 h at room temper-
ature (1:3000, Santa Cruz Biotechnology). Between each 
step, the membranes were washed two times for 5 min 
with TBS-T. Samples prepared in Laemmli buffer contain-
ing 2% (v/v) β-mercaptoethanol (β-MetOH) served as the 
control. β-Mercaptoethanol is a powerful reductant and is 
thus very effective at removing glutathionyl moieties from 
protein cysteine thiols. Thus, samples electrophoresed un-
der reducing conditions ensure that the observed immu-
noreactivity of PSSG antiserum is due to the presence of 
glutathionylated proteins. Immunoreactive bands were 
detected using enhanced chemiluminescent substrate 
for visualization (ECL kit, Thermo Scientific). Ponceau S 
staining of membranes served as a loading control. The to-
tal amount of glutathionylated proteins was then quanti-
fied using ImageJ software. 
Complex I Activity Assays. Mitochondria were treated 
with 1% (v/v) digitonin and incubated on ice for 30 min. 
Permeabilized mitochondria were then diluted to 0.5 mg/
ml in assay buffer (70 mm sucrose, 220 mm mannitol, 1 
mm EGTA, 2 mm HEPES, 10 mm KH2PO4, 5 mm MgCl2, 
0.2% w/v defatted BSA, pH 7.2) containing 2 mm KCN, 1 
μm antimycin A, with or without 10 mm DTT. Reactions 
were initiated by the addition of NADH (0.2 mm). The 
rate of NADH consumption was calculated for the first 30 
s to 1 min of the reaction because this represents the time 
for most rapid consumption of NADH. Reactions per-
formed in the absence of mitochondria or NADH served 
as controls. All values were corrected for background 
NADH consumption. 
The impact of 2GSH/GSSG and exogenous Grx1 on 
complex I activity was tested as described previously 
(24) with a few modifications. Digitonized mitochondria 
were incubated at 37 °C in different amounts of reduced 
and oxidized glutathione (GSH and GSSG, respectively) 
to provide 2GSH/GSSG ratios of 100 and 1, respectively. 
For mitochondrial preparations that were incubated with 
a 2GSH/GSSG of ~1, incubations were also performed in 
the absence or presence of 10 units of Grx1. Following a 
5-min incubation, complex I activity was tested. The po-
tential of the 2GSH/GSSG redox pair was calculated us-
ing Equation 2. 
Mitochondrial ROS Emission. Mitochondrial ROS pro-
duction kinetics were measured using dihydrodichlorofluo-
rescein diacetate in a BioTek SynergyMX2 microplate reader 
(Winooski, VT) using Gen5 software, as described previ-
ously (38). Mitochondria were diluted to 0.5 mg/ml in reac-
tion buffer (70 mm sucrose, 220 mm mannitol, 1 mm EGTA, 
2 mm HEPES, 10 mm KH2PO4, 5 mm MgCl2, 0.2% w/v de-
fatted BSA, pH 7.2) containing dihydrodichlorofluorescein 
diacetate (20 μm), 1 μg/ml oligomycin, with or without 10 
mm DTT. Reactions were initiated by the addition of pyru-
vate (10 mm) and malate (2 mm). Reactions devoid of mi-
tochondria served as the control. Values were corrected for 
background fluorescence. 
Metabolite Analysis. Mitochondria were diluted to 0.5 
mg/ml in perchloric acid solution and clarified as described 
above. Supernatants were then injected into an Agilent 
HPLC system equipped with a C18 reverse phase hydrophilic 
HPLC column (Synergy Hydro-RP, 4 μm, 250 × 4.6 mm; Phe-
nomenex) and operated at a flow rate of 0.7 ml/min. The 
mobile phase consisted of 20 mm KH2PO4 dissolved in dou-
ble distilled H2O, pH 2.9. TCA cycle intermediates and ATP 
were detected using an Agilent variable wavelength detector 
set to 210 and 254 nm. Retention times were confirmed by in-
jecting standard solutions. Levels of metabolites were quan-
tified using Agilent ChemStation software. 
Oxidative Damage. 4-Hydroxy-2-nonenal-histidine co-
valent adducts were measured using the OxiSelect ELISA 
kit provided by CellBio Labs (CellBio Labs, San Diego). As-
says were conducted according to the manufacturer’s in-
structions. 8-Hydroxy-2′-deoxyguanosine levels were mea-
sured by HPLC. Mitochondria were diluted to 0.5 mg/ml 
in perchloric solution and incubated on ice as described 
above. Following removal of precipitate, the clarified super-
natant was injected into an Agilent HPLC system equipped 
with a C18 reverse phase hydrophilic HPLC column (Syn-
ergy Hydro-RP, 4 μm, 250 × 4.6 mm; Phenomenex). Run 
conditions were the same as described above. 8-Hydroxy-
2′-deoxyguanosine was detected using an Agilent vari-
able wavelength detector set to 254 nm. Retention times 
were confirmed by injecting standard solutions. We also in-
jected 2′-deoxyguanosine standard solutions to ensure no 
overlap with the retention and detection of 8-hydroxy-2′-
deoxyguanosine. Levels of metabolites were quantified us-
ing Agilent ChemStation software. 
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Cytochrome c + c1 Concentration. Mitochondria were di-
luted to 1 mg/ml in BSA-free HM containing either excess 
sodium dithionite (reducing) or ferricyanide (oxidizing), as 
described previously (40, 41). Concentrations were deter-
mined by reading the maximum absorbance of mitochondria 
at 550 nm. The difference in absorbance under reducing and 
oxidizing conditions was then calculated and normalized 
to isosbestic points measured at 535 nm. The concentration 
of cytochrome c + c1 was determined according to the Beer-
Lambert law, as described previously (42), with a molar ex-
tinction coefficient of 18,500 m−1·cm−1. 
Immunoblots. Mitochondria were diluted to 2 mg/ml, 
and protein was electrophoresed and electroblotted as de-
scribed above. Ventricular heart tissue was mechanically 
homogenized in homogenization buffer (50 mm Tris, pH 
7.5, 1 mm EDTA disodium salt, 1 mm EGTA, 50 mm NaF, 
5 mm sodium glycerophosphate, 10% v/v glycerol, 1% v/v 
Triton X-100, 1 mm DTT, 1 mm PMSF), and protein con-
tent was determined by a BCA assay. Samples were electro-
phoresed on 15% isocratic, 12% isocratic, and 10% isocratic 
SDS gels to afford proper immunodetection of Grx2, thiore-
doxin-2 (Trx2), uncoupling protein 3 (UCP3), and manga-
nese superoxide dismutase (MnSOD). In addition, for Mn-
SOD determinations only 15 μg of protein was loaded into 
each well, whereas Trx2 and Grx2/UCP3 determinations 
required 45 and 60 μg of protein, respectively, for proper 
detection. Membranes were blocked and probed for 24 h at 
4 °C with primary antibodies directed against Grx2 (1:500, 
Abcam), Trx2 (1:1000, Abcam), UCP3 (1:1000, Abcam), and 
MnSOD (1:3000, Santa Cruz Biotechnology). Membranes 
were then incubated for 1 h at room temperature in the req-
uisite secondary HRP-conjugated antibody. Succinate de-
hydrogenase A or α-tubulin served as the loading control 
(1:2000, Santa Cruz Biotechnology) and (1:5000, Sigma) re-
spectively. Immunoreactive bands were visualized as de-
scribed above. 
Simultaneous detection of different respiratory com-
plex subunits was performed with the MitoProfile OX-
PHOS antibody mixture (Abcam). The mixture consisted 
of five different antibodies directed against a specific sub-
unit associated with each complex (I to V) as follows: 
NDUFB8, succinate dehydrogenase B, UQCRC2, MTCO1, 
and ATP5A. In bovine heart mitochondria, the ratio of com-
plexes I/II/III/IV/V is estimated to be 1.1:1.3:3:6.7:3.5 in-
dicating that the respiratory complexes vary in abundance 
(41). To afford proper detection and resolution of each com-
plex subunit, we electrophoresed 10 μg of mitochondrial 
protein for detection of UQCRC2, MTCO1, and ATP5A and 
45 μg of mitochondrial protein for NDUFB8 and succinate 
dehydrogenase B. Electrophoresis and protein amounts 
along with antibody dilution were optimized prior to ex-
perimentation. After blocking, membranes were probed 
overnight at 4 °C under constant agitation. OXPHOS an-
tibody was diluted by 1:800 in TBS-T supplemented with 
5% (w/v) defatted BSA and 0.02% (w/v) NaN3. After three 
washes in TBS-T membranes were probed with anti-mouse 
HRP conjugate. Immunoreactive bands were identified us-
ing molecular weight markers and quantified with ImageJ 
software. Quantification values were adjusted for the final 
amount of protein used for detection. 
NDUSF1 Glutathionylation. NDUSF1 glutathionylation 
was tested by immunoblot. Samples were loaded in dupli-
cate on gels to allow alignment of NDUSF1 immunoreac-
tive bands with PSSG immunoreactive bands that appear at 
the same molecular weight. Mitochondria were diluted to 2 
mg/ml in Laemmli buffer. 30 μg of sample was electropho-
resed in 12% isocratic SDS gels. Following transfer of pro-
teins to nitrocellulose membranes, membranes were stained 
with Ponceau S and then cut in half vertically to be probed 
for NDUSF1 and PSSG. As NDUSF1 has a molecular mass 
of ~75 kDa, blots were cut a second time horizontally be-
low the 50-kDa marker to measure MnSOD, which served as 
the loading control. All blots were incubated overnight un-
der constant agitation at 4 °C. NDUSF1 was diluted to 1:2000 
in TBS-T, 5% (w/v) defatted BSA, 0.02% (w/v) NaN3, and 
PSSG and MnSOD were diluted as described above. Experi-
ments were also performed on samples electrophoresed un-
der reducing conditions to ensure that the immunoreactive 
bands in the 75-kDa range were due to interaction of PSSG 
antiserum with glutathionylated proteins. 
Statistics. Statistical analysis was performed using 
GraphPad Prism 6 (GraphPad Software, La Jolla, CA). Com-
parison of controls with treated groups was performed with 
Student’s t test. For comparisons of multiple treatments in 
the same group with a control, one-way ANOVA with a post 
hoc Tukey’s test was used. 
Results
Grx2 Deficiency Induces Left Ventricular Hypertrophy 
and Moderate Fibrosis but Does Not Compromise Heart 
Contractility. Hearts from Grx2-deficient mice aged 9–12 
weeks weighed significantly more (Figure 1a). No changes 
in serum hemoglobin were observed indicating Grx2−/− mice 
are not anemic (Figure 1b). Increased heart weight was asso-
ciated with an increase in cardiomyocyte size and moderate 
left ventricular fibrosis in mice at 9 weeks of age; no left ven-
tricular fibrosis was observed at 6 weeks (Figure 1c). Histo-
logical analyses indicated concentric hypertrophy; there was 
no evidence of myocytolysis or myocyte disarray. Echocar-
diographic measurements revealed that the left ventricular 
wall was significantly thicker in Grx2-deficient mice (Figure 
1, d and e). Measurement of the size of the interventricular 
septum, left ventricular internal dimension, and left ventric-
ular wall in diastole and systole confirmed that the left ven-
tricle in Grx2−/− mice is hypertrophied (Table 1). Thus, the 
increased heart size is associated with hypertrophying of 
the left ventricle and fibrosis. We then calculated fractional 
shortening and ejection fractions, indices for diastolic and 
systolic function, and measured blood flow through the mi-
tral valve during diastole. No significant changes in frac-
tional shortening or ejection volume were observed (Figure 
1e). At 16 weeks of age, left ventricles were still hypertro-
phied (Table 2), and a small but significant increase in frac-
tional shortening and ejection volume was observed (Fig-
ure 1f). Despite this small increase in fractional shortening, 
overall cardiac function (contraction and relaxation) was 
maintained. 
We next examined heart glucose uptake in vivo using the 
glucose radiotracer analog [18F]FDG and microPET. Analysis 
of representative images showed stark visual differences in 
glucose uptake in the heart of Grx2−/− mice compared with 
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Table 1. Echocardiographic measurement of left ventricular size and function in diastole and systole in male mice 10 weeks of age. All 
measurements are in millimeters and were performed on M-mode images acquired with conscious mice. n = 7, mean ± S.E., Student’s t test. IVS 
is interventricular septum; LVID is left ventricular internal dimension; LVPW is left ventricular posterior wall; d is diastole; s is systole. 
 IVS, d  LVID, d  LVPW, d  IVS, s  LVID, s  LVPW, s
WT  0.68 ± 0.03  4.38 ± 0.18  0.65 ± 0.03  1.09 ± 0.04  3.12 ± 0.15  1.01 ± 0.03
Grx2 –/–  0.83 ± 0.02 a  4.92 ± 0.19 a  0.80 ± 0.03 b  1.18 ± 0.02 a  3.61 ± 0.17 a  1.14 ± 0.05 a
a. p < 0.05
b. p < 0.01
Figure 1. Grx2 deficiency induces cardiac hypertrophy and left 
ventricular fibrosis in 10-week-old mice. a, heart weight. Values 
were normalized to femur length (g/cm). n = 4, mean ± S.E., Student’s 
t test. b, serum hemoglobin levels. n = 6, mean ± S.E. c, histological 
analysis of cell size (H&E) and fibrosis (Sirius Red) in left ventricle. d, 
echocardiographic images of left ventricle in M-mode of mice aged 10 
weeks. Left ventricular wall parameters (Tables 1 and 2) calculate left 
ventricular wall mass, percent fractional contraction, and ejection ef-
ficiency in mice aged 10 weeks (e) and 16 weeks (f). n = 7, mean ± 
S.E., Student’s t test. 
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WT mice (Figure 2a). Three-dimensional polar mapping of 
the left ventricle revealed significantly higher [18F]FDG up-
take in this region of heart in Grx2−/− mice (Figure 2a). The 
rate of [18F]FDG uptake by the left ventricle and septum was 
also higher in Grx2−/− mice (Figure 2c). 
Impact of Grx2 Deficiency on Mitochondrial OXPHOS 
Proteins and Redox Environment. Electron microscopic anal-
ysis of sections from the left ventricle revealed no alterations 
in cristae structure (Figure 3a). However, sharp changes 
in the relative amounts of the various complexes were ob-
served (Figure 3b). Significant decreases in complex I acces-
sory protein NDUSB8, complex II subunit succinate dehy-
drogenase B, and complex IV subunit MTCO1 were evident 
in Grx2-deficient mitochondria. Intriguingly, Grx2 deficiency 
significantly increased the amounts of complex III subunit 
UQCRC2 and complex V subunit ATP5A (Figure 3b). Grx2 
deficiency also significantly increased the concentration of 
cytochrome c + c1 in mitochondria (Figure 3c). 
We next measured the impact of Grx2 deficiency on the 
redox potential of mitochondria and the total glutathionyl-
ated proteome. Grx2−/− cardiac mitochondria contained sig-
nificantly more GSSG than WT mitochondria (Table 3). In 
addition the total glutathione pool was significantly larger 
in Grx2−/− cardiac mitochondria suggesting that loss of Grx2 
induces glutathione biosynthesis in the cytosol (Table 3). Al-
though Grx2−/− mitochondria also contained more GSH, no 
significance was recorded in comparison with WT. In Grx2-
deficient mitochondria, 2GSH/GSSG was approximately a 
Figure 2. Glucose uptake is increased in the left ventricle of Grx2-efficient mice. a, [18F]FDG images collected from WT and Grx2−/− mice. 
Static images were collected after 60 min of imaging. White arrow represents location of heart. Asterisk denotes location of bladder. b, three-di-
mensional polar map of glucose uptake in left ventricle. Maps were generated after 60 min of imaging. The rate of myocardial glucose uptake 
(rMGU) by the left ventricle was then calculated. n = 4–5, mean ± S.E., Student’s t test. c, dynamic measurement of the rate of [18F]FDG uptake by 
left ventricle and septum. n = 4–5, mean ± S.E., Student’s t test. * denotes p < 0.05. 
Table 2. Echocardiographic measurement of left ventricular size and function in diastole and systole in male mice 16 weeks of age. All 
measurements are in millimeters and were performed on M-mode images acquired with conscious mice. n = 4, mean ± S.E., Student’s t test. IVS 
is interventricular septum; LVID is left ventricular internal dimension; LVPW is left ventricular posterior wall; d is diastole; s is systole. 
 IVS, d  LVID, d  LVPW, d  IVS, s  LVID, s  LVPW, s
WT  0.62 ± 0.02  4.46 ± 0.10  0.66 ± 0.04  0.95 ± 0.03  3.11 ± 0.10  1.06 ± 0.06
Grx2–/–  0.78 ± 0.02 a  4.09 ± 0.11 a  0.82 ± 0.05 b  1.08 ± 0.04 b  2.87 ± 0.08 b  1.24 ± 0.06 a
a. p < 0.01 
b. p < 0.05
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Figure 3. Grx2 deficiency alters content of respiratory complexes and redox environment. a, electron microscopic images of mitochondrial 
cristae structure in left ventricle. Scale bar, 500 nm. n = 3. b, immunoblot analysis of respiratory complex subunits. Protein bands were identified 
and quantified to determine respiratory complex subunit amounts. n = 3, mean ± S.E., Student’s t test. SDHB, succinate dehydrogenase B. c, ab-
solute content of cytochromes c and c1 in cardiac mitochondria. The absolute amounts were calculated from the difference in absorbance values 
when mitochondria were fully reduced (dithiothreitol) or fully oxidized (ferrocyanide). n = 4, mean ± S.E., Student’s t test. d, measurement of the 
mitochondrial 2GSH/GSSG ratio. Absolute amounts of reduced glutathione (GSH) and glutathione disulfide (GSSG) in mitochondria were mea-
sured by HPLC and then used to calculate the 2GSH/GSSG. The Eh of the ratio was then calculated using the Nernst equation. n = 4, mean ± 
S.E., Student’s t test. * denotes p < 0.05. e, immunodetection of PSSG in cardiac mitochondria. Electrophoresis was conducted under nonreducing 
(left) and reducing (right; + 2% v/v βMetOH). Bands were quantified using ImageJ software. n = 4, mean ± S.E., Student’s t test. 
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quarter of the WT ratio (Figure 3d). The lower 2GSH/GSSG 
had a significant effect on the potential (Eh) of the redox 
pair (Figure 3d). Previous reports have estimated that the Eh 
value of the 2GSH/GSSG varies between −280 and −340 mV 
(43). From our calculations, the Eh value in WT mitochondria 
falls within this range. Grx2 deficiency increases the Eh value 
of this pair creating a more oxidizing matrix environment. 
Grx2 is required to catalyze reversible glutathionylation, 
but changes in 2GSH/GSSG can also alter the glutathionyl-
ation state of proteins as well. Grx2 deficiency significantly 
increased the total amount of glutathionylated protein in 
cardiac mitochondria (Figure 3e). The specificity of the anti-
PSSG antibody was confirmed by performing electrophore-
sis under reducing conditions (+βMetOH). As shown in Fig-
ure 3e, addition of βMetOH abolished anti-PSSG antibody 
binding, except for a faint band at ~40 kDa. 
The increase in the Eh value of 2GSH/GSSG prompted 
us to determine whether Grx2 deficiency induced oxida-
tive damage or changes in the levels of antioxidative de-
fense and redox enzymes. No differences in the levels of 
4-hydroxy-2-nonenal-histidine adducts or 8-hydroxy-2′-
deoxyguanosine, two end products of ROS damage, were 
observed in Grx2-deficient heart mitochondria when com-
pared with WT (Figure 4, a and b). Thioredoxin-2 (Trx2) is 
required to reduce intra- or intermolecular disulfide bridges 
that may form during oxidative stress. No changes in Trx2 
protein levels were recorded (Figure 4c). Also, no changes in 
the protein levels of MnSOD were observed (Figure 4c). Col-
lectively, our results indicate that Grx2 deficiency changes 
mitochondrial redox, increases the glutathionylated pro-
teome, and alters the composition of the respiratory com-
plexes. However, these changes occurred in the absence of 
oxidative damage. 
Grx2 Deficiency Causes Dysfunctional Oxidative Phos-
phorylation. We next measured the impact of Grx2 defi-
ciency on cardiac mitochondrial energetics using a high 
throughput multiwell technique (28). Mitochondrial di-ox-
ygen consumption was measured sequentially under state 
2 (substrate only), state 3 (substrate + ADP), oligomycin-in-
duced state 4 (proton leak-dependent respiration), and fol-
lowing treatment with protonophore FCCP (Figure 5, a and 
b). No significant differences in proton leak-dependent res-
piration (state 4) were observed (Figure 5a). No significant 
change in UCP3 protein was observed (Figure 4c). Remark-
able, however, was the significantly lower rate of ADP-stim-
ulated (state 3) respiration (Figure 5a). Addition of DTT to 
reaction mixtures restored state 3 respiration in Grx2-defi-
cient cardiac mitochondria to WT levels (Figure 5b). Simi-
larly, uncoupled respiration was significantly lower in mi-
tochondria isolated from Grx2−/− (Figure 5a) but could be 
recovered to WT levels by the inclusion of DTT (Figure 5b). 
The observation that uncoupled respiration in Grx2−/− car-
diac mitochondria was also significantly decreased indicates 
that the decrease in OXPHOS is likely associated with a de-
crease in the activity of a respiratory complex or complexes 
rather than a decrease in ATP synthase activity. 
The decrease in state 3 respiration resulted in an RCR that 
was less than a half of the WT RCR (Figure 5c). Inclusion of 
DTT in reaction mixtures restored RCR values in Grx2−/− 
cardiac mitochondria to WT levels (Figure 5c). RCR was also 
significantly decreased (~50%) when palmitoylcarnitine was 
the respiratory substrate, and this was readily recovered by 
the addition of DTT (Figure 5c). The observed decrease in 
OXPHOS was confirmed by measuring absolute amounts of 
ATP in mitochondria respiring on pyruvate and malate (Fig-
ure 6). A significant decrease in ATP synthesis was observed 
in Grx2-deficient mitochondria. This was matched by signif-
icant decreases in various TCA cycle metabolites (Figure 6). 
ADP titration experiments revealed that Grx2 deficiency 
induced a modest decrease in the affinity of ATP synthase 
for ADP (Figure 5e). We also examined whether changes in 
respiration were due to damage to the outer membrane (e.g. 
during mitochondrial isolation and attachment to the surface 
of Seahorse TC plates). As shown in Figure 5f, no changes in 
respiration were recorded following treatment of mitochon-
dria with increasing concentrations of cytochrome c after in-
duction of state 3 respiration. 
Figure 4. Grx2 deficiency does not induce oxidative damage in 
cardiac mitochondria. a, measurement of 4-hydroxy-2-nonenal (4-
HNE) histidine adduct levels in isolated mitochondria. n = 4, mean ± 
S.E., Student’s t test. b, assessment of 8-hydroxy-2′-deoxyguanosine 
(8-OH-2′-deoxyguanosine) levels in isolated mitochondria. n = 4, mean 
± S.E., Student’s t test. c, immunoblot analysis of MnSOD, uncoupling 
protein-3 (UCP3) protein levels, Grx2, and Trx2. Succinate dehydroge-
nase (SDH) or α-tubulin served as loading controls. 
Table 3. Absolute GSH and GSSG levels in WT and Grx2−/− cardiac 
mitochondria. All values reported as mm/liter. Calculations were per-
formed as described under “Experimental Procedures.” n = 4, mean ± 
S.E., Student’s t test. 
   Total glutathione
 GSH  GSSG  (GSH + GSSG)
WT  2.39 ± 0.065  0.081 ± 0.014  2.47 ± 0.069
Grx2–/–  3.24 ± 0.39  0.27 ± 0.037 a  3.51 ± 0.41 b
a. p < 0.01
b. p < 0.05
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Impact of Grx2−/− and Redox Environment on Complex 
I Activity and Glutathionylation. The specific activity of 
complex I was significantly lower in Grx2-deficient cardiac 
mitochondria when compared with WT (Figure 7a). Incu-
bation in 10 mm DTT restored the activity of complex I in 
Grx2-deficient mitochondria to levels that were not signifi-
cantly different from those in WT mitochondria. We also 
measured ROS production in isolated mitochondria. Grx2-
deficient mitochondria respiring on complex I-linked sub-
strates pyruvate and malate generated more ROS under state 
4O conditions than WT cardiac mitochondria (Figure 7b). 
Performing the reactions in the presence of 10 mm DTT low-
ered ROS emission by Grx2-deficient cardiac mitochondria 
to WT levels. 
Complex I has previously been reported to be modu-
lated by glutathionylation (24, 27, 28). Thus, we next tested 
whether complex I activity can be recovered with exoge-
nously added Grx1 or GSH. We also wanted to determine 
Figure 5. Grx2 deficiency decreases complex I-supported oxidative phosphorylation, which can be restored with DTT. Measurement of 
O2 consumption in isolated cardiac mitochondria under different bioenergetic states was conducted using the Seahorse XF24. a and b, states 3, 
state 4, and FCCP-induced uncoupled respiration rates in the absence or presence of 10 mm dithiothreitol (DTT). Pyruvate and malate were used 
as substrates. Seahorse traces detailing the experiment are included in a and b. c, calculated respiratory control ratios for a and b. n = 4, mean ± 
S.E., Student’s t test. d, calculated respiratory control ratios for mitochondria respiring on palmitoylcarnitine. e, ADP titration assay; f, mitochondrial 
quality test. n = 3, mean ± S.E. Cyt c, cytochrome c; Ant A, antimycin A. 
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whether complex I activity in mitochondria from WT mice 
could be inhibited by adding excess GSSG. Addition of 10 
mm GSH and 0.1 mm GSSG did not alter complex I activ-
ity in WT cardiac mitochondria (Figure 7c). However, adjust-
ment of the 2GSH/GSSG to ~1 induced an ~50% decrease 
in complex I activity in WT mitochondria relative to control 
(Figure 7c). Addition of exogenous Grx1 restored the activ-
ity of complex I to control levels in mitochondria exposed to 
a 2GSH/GSSG of ~1 (Figure 7c). We next performed similar 
determinations on Grx2−/− mitochondria. As shown in Fig-
ure 7c, complex I activity was lower in Grx2−/− mitochon-
dria. This activity increased ~2.1-fold when 10 mm GSH was 
added (Figure 7c). Adjustment of the 2GSH/GSSG to ~1 did 
not decrease the activity of complex I any further, relative to 
control. Addition of exogenous Grx1 induced an ~2.3-fold 
increase in complex I activity relative to control even when 
the 2GSH/GSSG was set to ~1 (Figure 7c). These results il-
lustrate that Grx plays a central role in reversing the deac-
tivation of complex I by glutathionylation. In addition, our 
results indicate that redox potential plays an important role 
in modulating complex I activity. For instance, if the redox 
potential of 2GSH/GSSG is highly oxidizing, it can lead to 
spontaneous deactivation of complex I by glutathionyl-
ation. The opposite is also true for a highly reducing 2GSH/
GSSG, which spontaneously recovers complex I activity by 
deglutathionylation. 
The above results indicate that glutathionylation reac-
tions mediated by Grx2 regulate complex I activity. We also 
observed that excess GSSG can inhibit complex I. In a pre-
vious report, it was found that complex I subunit NDUSF1 
is glutathionylated by Grx2 (25). We next used comparative 
electrophoresis and immunoblotting to indirectly determine 
whether Grx2 deficiency alters the glutathionylation state of 
NDUSF1. Immunoblotting for protein glutathione disulfide 
adducts (PSSG) revealed protein bands at ~72–75 kDa that 
matched the electrophoretic mobility of NDUSF1 (Figure 7d). 
The PSSG bands at this molecular weight were quantified 
and normalized to the intensity of NDUSF1 immunoreactive 
bands. These results suggest that NDUSF1 was more gluta-
thionylated in mitochondria from the Grx2-deficient heart 
(Figure 7d). Intriguingly, NDUSF1 levels were ~10% higher 
in WT mitochondria. Immunoreactivity toward PSSG anti-
serum was abolished when samples were electrophoresed 
under reductive conditions (+βMetOH) confirming that the 
protein band detected at ~72–75 kDa was a glutathionylated 
protein (Figure 7d). These results suggest that NDUSF1 may 
be the site for glutathionylation of complex I. 
OXPHOS and Heart Physiology in Younger Grx2-defi-
cient Mice. Our above results demonstrate that mitochondria 
from hearts of Grx2-deficient male mice aged 9–12 weeks 
have decreased OXPHOS efficiency, which can be reversed 
by adding DTT. We next decided to test the impact of Grx2 
deficiency on mitochondrial energetics and heart physiol-
ogy in mice aged 6 weeks. To afford a comparison, we also 
measured OXPHOS and heart weights in mice that were 10 
weeks of age. In mice aged 10 weeks, hearts from Grx2-defi-
cient mice weighed significantly more than WT hearts (Fig-
ure 8a). These physiological changes coincided with a de-
crease in OXPHOS. Incubation of Grx2-deficient cardiac 
mitochondria in 10 mm DTT restored the efficiency of ATP 
production (Figure 8a). These observations are consistent 
with the results generated above. Intriguingly, hearts from 
6-week-old WT and Grx2−/− mice weighed the same, and 
there were no signs of hypertrophy in the Grx2−/− mice (Fig-
ure 8b). In addition, no differences in the efficiency of OX-
PHOS were observed between WT and Grx2-deficient car-
diac mitochondria (Figure 8b). 
Heart Physiology and OXPHOS in Grx2 Heterozy-
gotes. We next tested whether mice heterozygous for Grx2 
(Grx2+/−) also presented with abnormalities in OXPHOS. 
Weights of hearts from Grx2+/− and Grx2−/− mice were sim-
ilar and were heavier than hearts from WT mice (Figure 9a). 
The amount of Grx2 protein in Grx2+/− mitochondria was 
approximately half that in WT mitochondria (Figure 9b). We 
Figure 6. ATP and tricarboxylic acid intermediate levels in cardiac 
mitochondria are altered by Grx2 deficiency. Levels of various TCA 
cycle metabolites and ATP were measured by HPLC as described un-
der “Experimental Procedures.” n = 4, mean ± S.E., Student’s t test. 
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then tested the impact of Grx2+/− on OXPHOS efficiency. As 
shown in Figure 9c, mitochondria from Grx2+/− mice had de-
creased RCRs, similar to values from Grx2−/− mice (Figure 
9c). Treatment of mitochondria with 10 mm DTT recovered 
RCRs in mitochondria from Grx2+/− and Grx2−/− mice (Fig-
ure 9c). Left ventricular hypertrophy is often induced by 
hemodynamic stress. Thus, we assessed diastolic and sys-
tolic blood pressure to discern if hypertension and hemody-
namic stress were evident. At 9 weeks of age, systolic blood 
pressure in Grx2-deficient mice was the highest (Figure 9d). 
Systolic pressure was also elevated in mice heterozygous 
for Grx2 but not to the same magnitude as Grx2-deficient 
mice. No differences in diastolic pressure were observed at 
9 weeks of age (Figure 9d). Intriguingly, at 6 weeks the sys-
Figure 7. Complex I activity is 
compromised but is recovered 
by restoration of redox envi-
ronment. Measurement of com-
plex I activity (a) and mitochon-
drial ROS production (b) in the 
absence or presence of 10 mm di-
thiothreitol (DTT). n = 4, mean ± 
S.E., Student’s t test. c, complex I 
activity can be recovered by res-
toration of redox environment or 
the addition of exogenous glutare-
doxin-1 (Grx). Mitochondria were 
permeabilized and then incubated 
for 5 min in various combinations 
of reduced glutathione (GSH), ox-
idized glutathione (GSSG) in the 
absence or presence of 10 units 
Grx. Complex I activity was then 
measured. The Eh values were 
estimated according to the Nernst 
equation (see Equation 1). n = 5, 
mean ± S.E., 1-way ANOVA with 
a post hoc Tukey’s test. * denotes 
p < 0.05. d, estimation of the glu-
tathionylation state of complex I 
subunit NDUSF1 (~75 kDa) by im-
munoblot. Glutathionylation state 
was preserved by treating mito-
chondria with 25 mm N-ethylma-
leimide. To afford a proper elec-
trophoretic estimation of NDUSF1 
glutathionylation, NDUSF1 and 
PSSG levels were detected on 
the same gels. Samples were also 
electrophoresed under reducing 
conditions (+2% v/v βMetOH) as 
a control for PSSG immunodetec-
tion. Bands were quantified using 
ImageJ. n = 3, mean ± S.E., Stu-
dent’s t test. Mice were age 9–12 
weeks. 
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tolic blood pressure in Grx2 heterozygous mice was compa-
rable with WT (Figure 9d). By contrast, systolic blood pres-
sure in Grx2-deficient mice was still significantly elevated. 
At 6 weeks of age, diastolic blood pressure was significantly 
lower in Grx2-deficient mice and mice heterozygous for 
Grx2 compared with WT mice (Figure 9d). 
Discussion
Mitochondrial dysfunction contributes to the pathogen-
esis of a number of diseases, including neurological disor-
ders, obesity, type 2 diabetes, and cardiovascular disorders. 
Perturbations in mitochondrial function have also been as-
sociated with cardiac injury and heart failure (44). Studies 
have established that defects in mitochondrial bioenergetics 
are associated with development of heart disease. Dysfunc-
tional mitochondria in cardiac tissue can lead to energy star-
vation, which is associated with defects in the conversion of 
fuels into ATP (45). Recent work has shown that perturba-
tions in post-translational modifications that regulate OX-
PHOS, like acetylation, can result in heart disease (44). In 
particular, a recent study established that regulation of com-
plex I by acetylation in cardiac tissue is essential for respond-
ing to chronic increases in workload (44). In this study, we 
have established that Grx2 plays a central role in regulating 
OXPHOS efficiency in cardiac mitochondria. The importance 
Figure 8. Effect of age on OXPHOS 
and heart weight. a and b, measure-
ment of RCR in mitochondria isolated 
from WT and Grx2−/− mice aged 10 
and 6 weeks. RCR values were calcu-
lated by dividing absolute state 3 res-
piration rates by state 4O respiration 
rates. Hearts were weighed prior to ex-
perimentation and normalized to femur 
length (g/cm). n = 4, mean ± S.E., Stu-
dent’s t test. 
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of Grx2 in maintaining efficient mitochondrial respiration 
in cardiac tissue stems from its capacity to deglutathionyl-
ate target proteins like complex I. Loss of Grx2 led to the hy-
per-glutathionylation of the mitochondrial proteome and de-
creased OXPHOS efficiency. Grx2 deficiency was associated 
with cardiac hypertrophy and hypertension. Intriguingly, 
Grx2 heterozygous mice also had cardiac hypertrophy and 
a decrease in mitochondrial ATP production associated with 
defective complex I activity. However, Grx2 heterozygotes 
presented with a milder degree of hypertension suggesting 
that perturbations in mitochondria can contribute to devel-
opment of heart disease. To our knowledge, this is the first 
study to show that controlled glutathionylation reactions 
mediated by Grx2 are key for modulating cardiac mitochon-
drial energetics. In addition, we provide evidence that intrin-
sic factors, such as deregulation of redox signaling, can con-
tribute to development of heart disease. 
Complex I is a major site for respiratory chain control in 
the heart (46). Indeed, complex I can serve as a major thera-
peutic target for prevention of cardiac ischemic-reperfu-
sion injury (46). Thus, a need for a better understanding of 
the mechanisms that control complex I activity in cardiac tis-
sue is required. We confirmed that complex I is a major tar-
get for Grx2-mediated deglutathionylation and demonstrated 
that complex I activity was decreased with Grx2 deficiency 
and that this could be reversed with DTT, exogenous Grx1, 
or GSH. Importantly, similar observations have been made in 
previous studies where addition of DTT, exogenous Grx1, or 
simply adding GSH to reactions reversed glutathionylation 
and activated mitochondrial proteins like complex I or carni-
tine/acyl-carnitine carrier (25, 31, 47). We also provided evi-
dence that NDUSF1 subunit of complex I may be the site for 
glutathionylation of complex I. In addition, the band at ~72–
75 kDa was more glutathionylated mitochondria from Grx2-
deficient mice. β-MetOH abolished band reactivity at ~72–75 
kDa confirming that NDUSF1 is glutathionylated. This ob-
servation is in line with previous studies that showed that 
Cys531 and Cys704 on NDUSF1 are sites for glutathionylation 
(25). In addition, recent work has shown that NDUSF1 is a tar-
get for S-nitrosylation and S-oxidation reactions (25, 46). We 
also noted that NDUSF1 levels were ~11% higher in WT mi-
tochondria indicating Grx2 deficiency can also affect the ex-
pression of mitochondrial proteins. It is important to point 
out that other subunits for complex I, including Ndufv1 (~51 
kDa), have been shown to be glutathionylated in perfused iso-
lated mouse hearts (48). Another subunit with a mass of ~40 
kDa have also been shown to be glutathionylated (31). This 
coincides with the mass of the ND3 subunit of complex I that 
harbors Cys39, which can be modified by S-oxidation reactions 
(49). It has been reported that complex I transitions between 
activated (A-form) and deactivated (D-form) states that regu-
late its activity (50). In the transition to the D-form, Cys39 on 
Figure 9. Grx2 heterozy-
gotes. a, heart weight. Val-
ues were normalized to fe-
mur length (g/cm). b, Grx2 
protein levels. c, calcu-
lated RCR for isolated car-
diac mitochondria. Pyru-
vate and malate served as 
the respiratory substrate. n 
= 3, mean ± S.E., one-way 
ANOVA with Tukey’s post 
hoc test. d, measurement of 
systolic and diastolic blood 
pressure. n = 6, mean ± 
S.E., one-way ANOVA with 
a post hoc Tukey’s test, * 
and ** denote p < 0.05 and 
p < 0.01. Mice were aged 
9–12 weeks. 
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ND3 becomes accessible and thus amenable to S-oxidation. 
Thus, ND3 subunit could serve as an important site for reg-
ulation of complex I activity by glutathionylation (51). Simul-
taneous immunoblotting for specific subunits for all respira-
tory complexes revealed that Grx2 deficiency decreased the 
amount of complex I subunit NDUFB8. This subunit is an ac-
cessory protein that plays no catalytic role in complex I. How-
ever, NDUFB8 has been suggested to be required for super-
complex assembly in mitochondria (52). According to our 
results, complex I activity is influenced by its “state of gluta-
thionylation,” which is directly modulated by Grx2 and not 
by the decrease in NDUFB8. Indeed, inclusion of DTT, resto-
ration of 2GSH/GSSG, or addition of exogenous Grx1 fully 
recovered complex I activity in Grx2-deficient mitochondria. 
We also observed that high GSSG inhibited complex I activ-
ity in WT mitochondria, which is consistent with previous ob-
servations that if GSSG levels are high enough then glutathio-
nylation of complex I can proceed via a simple thiol exchange 
reaction (53, 54). Inclusion of exogenous Grx1 with GSSG pre-
vented the deactivation of complex I by GSSG in WT mito-
chondria. It is important to consider though that inclusion of 
GSSG at high concentrations may influence complex I activity 
by altering the redox state of other redox couples. Addition of 
GSSG can deplete NADPH pools and result in the oxidation 
of thioredoxin-2. However, based on our results and work 
published by others (24, 31), we can conclude that GSSG low-
ers complex I activity by glutathionylation and that this can be 
reversed by either restoring the mitochondrial redox environ-
ment or in the presence of Grx2. 
We also observed that Grx2 deficiency drastically al-
tered the protein levels of all other measured respiratory 
complex subunits and cytochrome c. We also observed that 
the TCA cycle metabolite pool was diminished. The loss of 
a functional TCA cycle and changes in the protein levels 
of the respiratory complexes would inevitably also impact 
OXPHOS capacity. Deletion of Grx2 resulted in the gluta-
thionylation of a number of mitochondrial proteins. Thus, 
Grx2 may have many mitochondrial protein targets, in-
cluding TCA cycle enzymes. Indeed, previous reports have 
shown that various TCA cycle enzymes can be glutathio-
nylated (22, 55, 56) and that cardiac ATP synthase is deacti-
vated by glutathionylation (57). In our study, we observed 
that Grx2 deficiency induced a modest decrease in the sen-
sitivity of ATP synthase toward ADP. However, it is also 
important to point out that adenine nucleotide transloca-
tor is also a target for glutathionylation, which may affect 
its capacity to exchange adenine nucleotides and would 
affect ATP synthase activity (58). Previous reports have 
shown that glutathionylation of the α subunit of ATP syn-
thase diminishes ATP production (33, 35). Although our 
results do indicate that ATP synthase could potentially be 
affected by Grx2 deficiency, further analyses must be con-
ducted to properly evaluate the sensitivity of ATP synthase 
in Grx2−/− mitochondria toward ADP. 
Our analyses also revealed defective cardiac mitochon-
drial energetics in Grx2-deficient mitochondria respiring on 
either complex I-linked substrates or fatty acids, consistent 
with a recent report that carnitine/acylcarnitine carrier is 
inhibited by glutathionylation (47). Importantly, glutathio-
nylation of carnitine/acylcarnitine carrier can be reversed 
by addition of exogenous Grx1 or DTT in vitro (47). It is im-
portant to acknowledge that fatty acid oxidation in mito-
chondria serves as the main source of ATP in cardiac tissue. 
Indeed, this inability to use fatty acids or TCA cycle sub-
strates was associated with increased glucose uptake and 
reliance on glycolysis to produce ATP. Decreased OXPHOS 
in cardiac mitochondria induces a shift toward glycolysis to 
preserve ATP pools (59). Notably, we have demonstrated 
that the addition of DTT to Grx2-deficient cardiac mito-
chondria restored OXPHOS, thus indicating that the pri-
mary cause of the observed defects in mitochondrial func-
tion were due to perturbed redox and glutathionylation 
reactions. 
Hearts from 9- to 12-week-old Grx2-deficient mice were 
heavier and presented with left ventricular hypertrophy 
and fibrosis. Grx2-deficient mice were also hypertensive 
indicating that hemodynamic stress may be responsible 
for the hypertrophying of the left ventricle. In Grx2+/− 
mice, hearts were also hypertrophied, and ATP produc-
tion was decreased to values half those of WT controls. 
As in Grx2−/− mitochondria, OXPHOS could be fully re-
covered by the addition of DTT to reaction mixtures. In-
triguingly though, systolic blood pressure in 6-week-old 
Grx2+/− mice was not significantly different compared 
with WT mice. At 9 weeks, increased blood pressure was 
observed in Grx2+/− mice, but the levels were not as high 
as in Grx2−/− mice. Left ventricular hypertrophy is often 
associated with increased hemodynamic stress associ-
ated with hypertension (60). However, deregulated ATP 
production by mitochondria has also been implicated in 
left ventricular hypertrophy, which would indicate that 
cardiac disease can be caused by intrinsic (cardiac mito-
chondrial dysfunction) and extrinsic stress (hemodynamic 
stress) (61). Thus, the cardiac hypertrophy in mice hetero-
zygous for Grx2 is likely more directly associated with de-
regulated mitochondrial glutathionylation and inefficient 
ATP production, whereas in Grx2−/− mice left ventricu-
lar hypertrophy and fibrosis are due to a mixture of ex-
trinsic and intrinsic stressors (hemodynamic stress and 
inadequate mitochondrial ATP production). It is impor-
tant to note that Grx2−/− did not induce oxidative dam-
age, oxidative stress, or changes in mitochondrial ultra-
structure. Although we cannot exclude the possibility that 
the increased ROS production by mitochondria and de-
creased 2GSH/GSSG ratio may also contribute to the ob-
served hypertrophy, it can be concluded that deregulated 
mitochondrial glutathionylation reactions are responsi-
ble, in part, for the observed cardiac hypertrophy. It has 
been previously reported that myocardial overexpression 
of Grx2 maintains mitochondrial OXPHOS in mice treated 
with doxorubicin, a chemotherapeutic that can induce car-
diac dysfunction (34). Also, Brautigam et al. (62) observed 
that silencing Grx2 in zebrafish does not induce oxidative 
stress but does induce neuronal cell death due to changes 
in redox and possibly protein glutathionylation. 
This is the first study to investigate the relationship be-
tween Grx2-mediated regulation of mitochondrial bioener-
getics and heart function. We demonstrated that Grx2 is a 
key component of the regulatory machinery of cardiac mi-
tochondria. Loss of Grx2 function leads to deregulated mito-
chondrial glutathionylation, changes in mitochondrial redox 
state, and decreased mitochondrial ATP output. Our work 
also revealed that OXPHOS can be recovered by restoring 
the reductive nature of the mitochondrial redox environ-
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ment. Collectively our findings illustrate that redox signal-
ing plays a vital role in regulating mitochondrial OXPHOS 
in the heart and that disruption of glutathionylation reac-
tions can lead to heart disease. The observation that glutathi-
onylation status and mitochondrial function can be restored 
with reducing agents also indicates that therapies could po-
tentially be designed to restore the mitochondrial glutathi-
ome and thereby curtail the progression of heart disease. 
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